ModerateImmunosuppressants. Calcineurin inhibitors×Selective COX-2 inhibitor (coxib)
Updated · Methodology
Mechanism
A dose-dependent rise in serum creatinine and urea is a common and potentially serious complication of ciclosporin treatment (ciclosporin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The Spanish ciclosporin SmPC lists non-steroidal anti-inflammatory drugs (NSAIDs) among drugs with synergistic nephrotoxicity (AEMPS). According to the US label, NSAIDs used with ciclosporin may potentiate renal dysfunction, particularly in dehydration (ciclosporin label, US Food and Drug Administration, FDA). Etoricoxib is an NSAID. When renal perfusion is compromised, it can reduce renal prostaglandin formation and, as a result, renal blood flow and renal function (etoricoxib SmPC, AEMPS). The combination with etoricoxib has not been studied, but the etoricoxib SmPC states that any NSAID may increase the nephrotoxic effect of ciclosporin (AEMPS). The rise in diclofenac levels with ciclosporin is most likely due to a reduction of its high first-pass effect. No such rise is expected for NSAIDs with a low first-pass effect, such as acetylsalicylic acid (ciclosporin SmPC, AEMPS). The absolute oral bioavailability of etoricoxib is about 100% (etoricoxib SmPC, AEMPS).
Symptoms
Ciclosporin commonly raises serum creatinine and urea, and with long-term treatment some patients may develop structural kidney changes such as interstitial fibrosis (ciclosporin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Ciclosporin increases the risk of hyperkalaemia, especially in renal impairment (AEMPS). With non-steroidal anti-inflammatory drugs (NSAIDs), renal dysfunction may get worse, particularly in dehydration (ciclosporin label, US Food and Drug Administration, FDA). With etoricoxib, proteinuria, raised serum creatinine and renal failure are uncommon. Fluid retention, oedema and high blood pressure have been seen in people taking it (etoricoxib SmPC, AEMPS).
Management
The combination is not contraindicated. Use ciclosporin with caution together with drugs that have synergistic nephrotoxicity, including non-steroidal anti-inflammatory drugs (NSAIDs), and closely monitor renal function throughout concomitant use. If renal function becomes significantly impaired, reduce the dose of the other drug or consider alternative treatment (ciclosporin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Monitor renal function when etoricoxib and ciclosporin are used together (etoricoxib SmPC, AEMPS). In rheumatoid arthritis, ciclosporin can be combined with low doses of corticosteroids and/or NSAIDs. Check renal function more often when an NSAID is started or its dose is increased (ciclosporin SmPC, AEMPS). The US label says to monitor clinical status and serum creatinine closely when ciclosporin is used with NSAIDs in rheumatoid arthritis. In rheumatoid arthritis and psoriasis, it advises checking serum creatinine after starting an NSAID or increasing its dose (ciclosporin label, US Food and Drug Administration, FDA). Etoricoxib is contraindicated at creatinine clearance below 30 mL/min. Start it with caution in dehydrated patients. Rehydration before treatment is advisable (etoricoxib SmPC, AEMPS). If renal function worsens during treatment, take appropriate measures and consider stopping etoricoxib (etoricoxib SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica Sandimmun Neoral 100 mg cápsulas blandas (ciclosporina) (2026)– AEMPS, CIMA, nº registro 60320, revisión 04/2026, sección 4.5
- FDA: Neoral (cyclosporine) – Prescribing Information (2026)– FDA, DailyMed SPL, Novartis, Precautions (Drug Interactions)
- AEMPS: Ficha técnica: Etoricoxib, Arcoxia 120 mg (nº registro 64930), secciones 4.3, 4.4 y 4.5 (2021)– AEMPS, CIMA, nº registro 64930, revisión 05/2021, secciones 4.3, 4.4 y 4.5